Climb Bio enters $100M ATM equity facility with Jefferies, terminates prior Oppenheimer agreement

Climb Bio, Inc.

Enters $100M at-the-market equity distribution agreement with Jefferies LLC for common stock sales.
Jefferies will receive up to 3.0% of gross sales price per share; proceeds to fund general corporate purposes.
Terminates prior $22.35M ATM facility with Oppenheimer & Co.; no shares were sold, no penalties incurred.
Shares sold from time to time on Nasdaq Global Market at prevailing market prices.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 1.0

Climb Bio, Inc. entered into Open Market Sale Agreement with Jefferies LLC valued at up to $100.0 million in aggregate offering price (effective 2026-06-12).

Action: entry
Agreement: atm program
Counterparty: Jefferies LLC
Value: up to $100.0 million in aggregate offering price
Effective: 2026-06-12

Exact text from the filing

On June 12, 2026, Climb Bio, Inc., a Delaware corporation (the “Company”), entered into an Open Market Sale AgreementSM (the “Sales Agreement”) with Jefferies LLC, as agent (“Jefferies”), pursuant to which the Company may offer and sell shares of its common stock, $0.0001 par value per share (the “Common Stock”), from time to time through Jefferies.

View on SEC.gov

801 material agreements filed in the last 30 days. Browse all material agreements →

Climb Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-269567

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.